Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Edwards Lifesciences (EW) Free Cash Flow (2016 - 2026)

Edwards Lifesciences has reported Free Cash Flow over the past 17 years, most recently at $353.5 million for Q4 2025.

For Q4 2025, Free Cash Flow rose 299.38% year-over-year to $353.5 million; the TTM value through Dec 2025 reached $1.3 billion, up 360.5%, while the annual FY2025 figure was $1.3 billion, 360.5% up from the prior year.
Free Cash Flow for Q4 2025 was $353.5 million at Edwards Lifesciences, down from $516.2 million in the prior quarter.
Over five years, Free Cash Flow peaked at $516.2 million in Q3 2025 and troughed at -$177.3 million in Q4 2024.
A 5-year average of $232.4 million and a median of $251.3 million in 2022 define the central range for Free Cash Flow.
On a YoY basis, Free Cash Flow climbed as much as 2100.7% in 2024 and fell as far as 467.08% in 2024.
Year by year, Free Cash Flow stood at $283.8 million in 2021, then dropped by 24.63% to $213.9 million in 2022, then crashed by 77.42% to $48.3 million in 2023, then plummeted by 467.08% to -$177.3 million in 2024, then soared by 299.38% to $353.5 million in 2025.
Business Quant data shows Free Cash Flow for EW at $353.5 million in Q4 2025, $516.2 million in Q3 2025, and $240.9 million in Q2 2025.